Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors Show a Growing Promise within the Field of Cardiology
- Division of Cardiology, Department of Medicine, University of Texas Health Science Centre at San Antonio, San Antonio, TX, USAInterests: cardiovascular disease; hyperlipidemia; atherosclerosis; diabetes mellitusSpecial Issues and Topics in IMR Press journalsSpecial Issue in SGLT2 Inhibition: New Insight in Cardiology
The effective management of cardiac risk factors is a pivotal step, given that cardiovascular disease stands as a leading contributor to illness and mortality. Despite the continuous advancement of interventional technologies, medical therapy remains the cornerstone of treatment. Notably, Glucagon Like Peptide-1 Receptor Agonists (GLP-1 RA) have demonstrated significant efficacy, not only in diabetes management but also in achieving substantial weight loss. Obesity remains a pervasive and inadequately addressed pandemic. It directly or indirectly predisposes individuals to numerous cardiac risk factors, including hypertension, hyperlipidemia, diminished functional capacity, and an increased susceptibility to heart failure and cardiac arrhythmias.
Sodium Glucose co-Transporter-2 (SGLT-2) inhibitors have shown merit in diverse cardiac conditions, such as in the prevention of myocardial infarction in patients with atherosclerosis, improving the outcomes in heart failure cases with reduced and/or preserved left ventricular function, reducing mortality rates, and decreasing hospital admissions due to heart failure. Conversely, while GLP-1 RA have garnered recommendations for patients dealing with diabetes and cardiovascular atherosclerosis, their role in addressing other cardiac conditions remains a subject of ongoing debate.
It is worth noting that both GLP-1 RA and SGLT-2 inhibitors are under-utilized in the overall treatment of diabetic and cardiovascular patients. Furthermore, the emerging results of combination therapy involving GLP-1 RA and SGLT-2 inhibitors hold promise, shedding light on the expanding potential of GLP-1 RA in an era where SGLT-2 inhibitors have already established their value in cardiology.
Prof. Robert J. Chilton and Dr. Badr Harfouch
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.